Halozyme Therapeutics Inc.
HALO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.39B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $11.39 Billion |
|---|---|
| Enterprise Value | $13.61 Billion |
| Earnings per Share | $2.64 |
| Beta | 0.9 |
| Outstanding Shares | 113,797,000 |
Return
| Return on Equity | -878.76% |
|---|---|
| Return on Assets | 13.98% |
| Return on Invested Capital | 34.14% |
Valuation & Multiples
| P/E Ratio | 23.87 |
|---|---|
| PEG | 58.24 |
| Price to Sales | 6.68 |
| Price to Book Ratio | -100.27 |
| Enterprise Value to Revenue | 7.55 |
| Enterprise Value to EBIT | 13.3 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | -58.84 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS
$2.39
Est. $2.30Revenue
$492.97 M
Est. $491.63 MNext Earnings Call
Expected Date
February 16, 2027
EPS Estimate
$2.57
Consensus analyst estimateRevenue Estimate
$551.44 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 150.00, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.
| Put/Call Ratio | 150.0000▲ 14938.33% |
|---|---|
| Total Calls | 100▼ 99.98% |
| Total Puts | 15,000▼ 94.60% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.61%▼ 86.84% |
|---|---|
| Total Invested | $2.40B▼ 75.29% |
| Investors Holding | 376▼ 314.00% |
About Halozyme Therapeutics Inc.
423 employees
CEO: Helen Torley
Halozyme Therapeutics, Inc., a biopharmaceutical technology company, was established in 1998 and is based in San Diego, California. The company's operations span globally, covering markets in the United States, Switzerland, Ireland, Belg...